MAT2A and nasopharyngeal carcinoma: Importantly, MTAP-null C666-1 cells demonstrated heightened sensitivity (~8.7-fold more sensitive) to the MAT2A inhibitor, FIDAS-5, compared with MTAP-wild-type NPC cell lines (Fig. 7E).